27492-46-2

Upstream product

• 100-52-7 benzaldehyde 
• 135636-66-7 butane-2,3-dione mono-oxime 
• 7647-01-0 hydrogenchloride 
• 57-71-6 2,3-Butanedione monoxime 

Downstream Products

• 851179-99-2 3-methoxyimino-2-{4-[2-(5-methyl-2-phenyl-oxazole-4-yl)-ethoxy]-benzyl}-butyric acid methyl ester 
• 932024-94-7 3-ethoxyimino-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-butyric acid methyl ester 
• 932024-99-2 3-methoxyimino-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-pentanoic acid methyl ester 
• 932024-95-8 2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-3-propoxyimino-butyric acid methyl ester 
• 932025-00-8 3-ethoxyimino-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-pentanoic acid methyl ester 
• 932024-96-9 3-isobutoxyimino-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-butyric acid methyl ester 
• 932024-98-1 3-cyclopropylmethoxyimino-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-butyric acid methyl ester 
• 932024-97-0 3-butoxyimino-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-butyric acid methyl ester 
• 932025-01-9 3-(4-fluoro-benzyloxyimino)-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzyl}-butyric acid methyl ester 

Relevant academic research and scientific papers

1,3-Oxazole-isoniazid hybrids: Synthesis, antitubercular activity, and their docking studies

A series of novel N′-([2-aryl-5-methyl-1,3-oxazole-4-yl]methylene)isonicotino/nicotino hydrazides 10a-l were prepared by the condensation reaction of 2-aryl-5-methyl-1,3-oxazole-4-carbaldehydes 8a-f with the corresponding isonicotino/nicotino hydrazides 9

New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity

We screened a short series of new chiral diphenylmethane derivatives and identified potent dual PPARα/γ partial agonists. As both enantiomers of the most active compound 1 displayed an unexpected similar transactivation activity, we performed docking expe

Design and synthesis of Oxime ethers of β-oxo-γ-phenylbutanoic acids as PPAR a and -γ dual agonists

Oxime ethers of p-oxo-y-phenylbutanoic acids were prepared to develop more effective PPAR a and y dual agonists. Among them, compound 11k exhibited potent in vitro activities with EC50 of 2.5 nM and 3.3 nM in PPAR a and y, respectively. It showed better g

First synthesis of the N(1)-bulky substituted imidazole 3-oxides and their complexation with hexafluoroacetone hydrate

Synthesis of new 2-unsubstituted imidazole 3-oxides bearing bulky substituents at the N(1) atom, based on the condensation of appropriate alkylamines, formaldehyde, and corresponding a-(hydroxyimino)ketone, is described. Treatment of imidazole 3-oxides with hexafluoroacetone hydrate (HFAH) yields crystalline 1:1 complexes in nearly quantitative yields. Heating of isolated complexes possessing phenyl ring at the C(4) atom of imidazole ring, results in their isomerization into imidazol-2-ones in fair yields. The formation of analogous complexes of HFAH with other azole N-oxides is also described. ARKAT-USA, Inc.

Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes

Design, synthesis, and SAR of novel α-alkoxy-β-arylpropionic acids as potent and balanced PPARαγ coagonists are described. One representative thereof, Aleglitazar ((S)-2Aa), was chosen for clinical development. Its X-ray structure in complex with both receptors as well as its high efficacy in animal models of T2D and dyslipidemia are also presented.

SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD

Compounds are provided which have the structure of Formula (I): wherein R is hydrogen or C1-C4 alkyl; and each of R1 and R2 is independently hydrogen, C1-C4 alkyl, halo or C1-Cs

CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

An object of the present invention is to provide novel carbazole derivatives, solvates thereof, or pharmaceutically acceptable salts thereof having an excellent adipose tissue weight reducing effect, hypoglycemic effect, and hypolipidemic effect, which are useful as a preventive and/or therapeutic agent for fatty liver, obesity, lipid metabolism abnormality, visceral adiposity, diabetes, hyperlipemia, impaired glucose tolerance, hypertension, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and the like. The above-mentioned object can be achieved by carbazole derivatives, solvates thereof, or pharmaceutically acceptable salts thereof, wherein the carbazole derivatives are represented by the following general formula (I): (In the formula (I), the ring A represents phenyl group or the like; X represents -O- or the like; Y represents =N- or the like; a and b represent methylene group or the like; both V and Z represent -O- or the like; W represents a C1-C10 alkylene group whose 1 or 2 hydrogen atoms may be substituted by a phenyl group or a C1-C6 alkyl group; 1,2-phenylene group; 1,3-cyclohexyl group; or the like; R1 represents methyl group or the like; R2 represents methoxy group or the like; and R3 represents carboxy group or the like.)

Design and synthesis of oxime ethers of α-acyl-β-phenylpropanoic acids as PPAR dual agonists

Oxime ethers of α-acyl-β-phenylpropanoic acids were prepared to apply as PPARα and γ dual agonists. Among them, compound 11l proved to exhibit potent in vitro activities with EC50 of 19 and 13 nM in PPARα and γ, respectively. It showed better g

Structure-based design of indole propionic acids as novel PPARα/γ co-agonists

In the quest for novel PPARα/γ co-agonists as putative drugs for the treatment of type 2 diabetes and dyslipidemia, we have used a structure-based design approach to identify propionic acids with a 1,5-disubstituted indole scaffold as potent PPARα/γ activ

Preparation of 2-(1-chloroalkyl)-4,5-dimethyloxazoles and (E)2-alkenyl-4,5-dimethyloxazoles

2-(1-Chloroalkyl)-4,5-dimethyloxazoles were prepared in 84-91% yields by simultaneous reduction and regioselective chlorination of the corresponding unstable N-oxides with POCl3 or SOCl2. Dehydrochlorination of 2-(1-chloroalkyl)-4,5-